Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors

• Main Authors: Danop Nanegrungsunk, Nattayaporn Apaijai, Chontida Yarana, Jirapas Sripetchwandee, Kriengsak Limpastan, Wanarak Watcharasaksilp, Tanat Vaniyapong, Nipon Chattipakorn, Siriporn C. Chattipakorn
• Format: Journal
• Published: 2018
• Subjects: Medicine; Neuroscience
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84978422190&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/56162
• Institution: Chiang Mai University

© 2016 Informa UK Limited, trading as Taylor & Francis Group. Objective: Current chemotherapy treatments available for treating high-grade brain tumors, Temozolomide (TMZ) or Bevacizumab (BEV), not only have specific anti-tumor mechanisms, but also have an effect on mitochondria. However, effe...